Companies in the News


  • Phase 1/2 trial ongoing with multiple patients dosed in GB1275 monotherapy dose escalation –

  • GB1275 granted Orphan Drug Designation for the treatment of pancreatic cancer by the U.S. Food and Drug Administration –

  • Preclinical data for GB1275 featured as cover article in July 3rd edition of S...


Program addresses aggressive cancers with RTK (HER2, ERBB3, FGFR1, FGFR2) and KRAS mutations

SAN DIEGO, November 5, 2019 — eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced the dosing of the first subject in the...


EMERYVILLE, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced data on novel shared tumor-specific neoantigens (TSNA) arising from...

Please reload